Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

2025 earnings conference call. My name is Alex. I'll be coordinating the call for today. If you'd like to ask a question once the presentation has finished, please press start, followed by one on your telephone keypad. I'll now hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead. Thank you, Alex. Good morning and good afternoon, everyone. On this call, we'll be making forward-looking statements, And we disclaim any obligation to update those statements after today's call. If you have more questions about our forward-looking statements, please feel free to see our disclosures under SEC Forms 10-Q and 10-K. Also during today's call, we'll be often referring to sales growth in local currency, as well as sales growth excluding the prior year results of our recently divested Japanese business venture. So please bear that in mind. And with that, let me turn it over to Richard. Thank you, Steve. Thank you, Chris, even. And welcome, everybody. Good morning. Thank you for joining the call. I'll be joined today with Eric Hughes, my head of R&D and CMO, who will be walking you through the pipeline. And Eli Khalif, CFO, will go through the financial update. So starting with, as I always do, the pivot to growth slide. Next slide, please. The four... Pillars are up here to go. So we've been executing this since 2023, and I'm pleased to say it's delivered continuous growth and we enter a 10th consecutive quarter of growth. Now, I'll give you an update on how we're doing on all of these pillars today, but you'll see on deliver on our growth engines are in it. Innovative portfolio of Stato, you said in a job, he continues to perform really well on step up innovation. Eric will walk you through how excited we are by our late stage pipeline and how we're progressing t...